Paradigm Therapeutics

Mt Pleasant, US · 1 known investors

Paradigm Therapeutics is a biopharmaceutical company developing Zorblesia (SD-101), a proprietary topical whole-body therapy for treating the wounds, lesions, and infections associated with all subtypes of Epidermolysis Bullosa (EB), a rare genetic connective tissue disorder. The company focuses on discovering and delivering therapies for patients with serious, life-threatening diseases.

BiotechHealthtechMedical Devices